(4,4-dimethyl-pentyl)-magnesium bromide | 96056-56-3

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 英文名称: (4,4-dimethyl-pentyl)-magnesium bromide
• 英文别名: 4,4-dimethylpentylmagnesium bromide
• CAS: 96056-56-3
• 化学式: C₇H₁₅BrMg
• 分子量: 203.405
• InChiKey: CVSNYHCYVCTLQI-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  3.25
• 重原子数：
  9.0
• 可旋转键数：
  3.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  0.0

反应信息

• 作为反应物：
  描述：

  (4,4-dimethyl-pentyl)-magnesium bromide 在 sodium 作用下， 以 乙醚 为溶剂， 生成 13,13-dimethyl-tetradecanoic acid methyl ester
  参考文献：
  名称：

  Streibl,M. et al., Collection of Czechoslovak Chemical Communications, 1964, vol. 29, p. 2522 - 2527

  摘要：

  DOI：

文献信息

• Lead tetraacetate oxidation of saturated aliphatic alcohols—IV
  作者：M.Lj. Mihailović、Ž. C̆eković、D. Jeremić

  DOI：10.1016/s0040-4020(01)98366-8

  日期：1965.1

  The lead tetraacetate oxidation of saturated aliphatic alcohols, with structures which do not permit 1,5-cyclization, gave tetrahydropyran derivatives in yields not exceeding 16%. The formation of a small amount of the rearranged ether, 2-ethyl-2-methyltetrahydrofuran, from 4,4-dimethyl-1-pentanol indicates that the cyclization reaction proceeds via an intermediate with carbonium ion character.

  具有不允许1，5-环化的结构的饱和脂族醇的四乙酸铅氧化，得到的四氢吡喃衍生物的产率不超过16％。由4，4-二甲基-1-戊醇形成的少量重排的醚2-乙基-2-甲基四氢呋喃表明环化反应是通过具有碳酸根离子特征的中间体进行的。
• [EN] GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] ANTAGONISTE DES RECEPTEURS DU GLUCAGON, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005123668A1

  公开（公告）日：2005-12-29

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明公开了具有胰高血糖素受体拮抗剂或逆拮抗剂活性的化合物I的新化合物，或其药用可接受的盐，以及制备这些化合物的方法。在另一实施例中，本发明公开了包含化合物I的药物组合物，以及使用它们治疗糖尿病和其他与胰高血糖素相关的代谢性疾病等方法。
• Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
  申请人：Conner Eugene Scott

  公开号：US20070249688A1

  公开（公告）日：2007-10-25

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明公开了化合物I式的新型化合物，或其药学上可接受的盐，其具有葡萄糖高素受体拮抗剂或反向激动剂活性，以及制备这些化合物的方法。在另一种实施方式中，本发明还公开了包括I式化合物的药物组合物，以及使用它们治疗糖尿病和其他与葡萄糖高素相关的代谢性疾病的方法等。
• Glucagon receptor antagonists, preparation and therapeutic uses
  申请人：Eli Lilly and Company

  公开号：US07816557B2

  公开（公告）日：2010-10-19

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明披露了I式新化合物或其药学上可接受的盐，具有胰高血糖素受体拮抗剂或反向激动剂活性，以及制备该类化合物的方法。在另一实施例中，本发明披露了包含I式化合物的药物组成物，以及使用它们治疗糖尿病和其他胰高血糖素相关代谢紊乱等方法。
• GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
  申请人：CONNER Scott Eugene

  公开号：US20110124648A1

  公开（公告）日：2011-05-26

  The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

  本发明披露了式I的新型化合物或其药学上可接受的盐，其具有胰高血糖素受体拮抗剂或反向激动剂活性，以及制备这种化合物的方法。在另一种实施方式中，本发明还披露了包含式I化合物的药物组合物，以及使用它们治疗糖尿病和其他胰高血糖素相关代谢紊乱等疾病的方法。